Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S100 calcium-binding protein A5 (S100A5) is a member of the S100 family of proteins characterized by two EF-hand calcium-binding motifs[1][3][6]. It has unusually high affinity for Ca²⁺ (20- to 100-fold higher than other S100 proteins) and can also bind Zn²⁺ and Cu²⁺, with strong Cu²⁺ binding inhibiting Ca²⁺ binding[1][3][6]. S100A5 is expressed in restricted regions of the adult brain, including the olfactory bulb and parts of the brain stem[1][5]. Like other S100 proteins, S100A5 is localized in the cytoplasm and/or nucleus and is involved in regulating a range of cellular processes, notably cell cycle progression and differentiation[1][3][6]. Upon calcium activation, S100A5 can interact with the receptor for advanced glycation end products (RAGE), suggesting a role in inflammation signaling[6]. While some S100 proteins are implicated in diseases such as cancer, inflammation, and neurodegeneration, specific disease associations for S100A5 remain limited, though related family links have been noted[3][5][6]. There are currently no known drugs or approved biomarkers directly targeting S100A5.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S100 calcium-binding protein A5 (S100A5).